Are Incentive-Based Formularies Inversely Associated with Drug Utilization in Managed Care?

Abstract

Spanish

French

OBJECTIVE:

To review recent studies comprehensively assessing the impact of incentive-based multitier formularies on pharmaceutical costs and utilization.

DATA SOURCES:

PubMed (2001–December 2003) was searched using the key terms formularies, cost-sharing, and drug costs. STUDY SELECTION AND DATA EXTRACTION: Studies addressing the impact of implementing multitiered incentive-based formularies as a central component of an outpatient drug benefit were selected.

DATA SYNTHESIS:

One study using pharmacy claims from 25 employers with data from 402 786 members modeled the range of anticipated plan/employer savings associated with single- to 3-tier shifts and found that, going from a single- to 3-tier benefit results in decreased plan/employer pharmaceutical costs from $650 to $494 (24% decrease) per member per year and decreased pharmaceutical utilization from 12.3 to 9.4 (23.6% decrease) prescriptions per member per year. Another study demonstrated that adding an additional tier decreased pharmaceutical utilization, with a dramatic increase in member contribution offsetting the plan's expected increase in expenditures. This shift in pharmaceutical expenditures appeared to have no effect on overall medical utilization over a 3-year follow-up. Finally, a study converting members from a single- to 3-tier incentive-based formulary, associated with two- to fourfold copayment increases, resulted in a 10% discontinuation rate for angiotensin-converting enzyme inhibitors, statins, and proton-pump inhibitors among members who were primarily hourly employees. For salaried workers, the addition of a tier to their benefit appeared to have minimal impact on pharmaceutical utilization.

CONCLUSIONS:

Emerging data suggest a potential inverse relationship between pharmaceutical utilization and incentive-based formularies that increase member contribution to drug costs. Future research should focus on identifying price points and percentage increases at which members are likely to begin discontinuing necessary medications.

Keywords

cost-sharing drug utilization formularies managed care

Get full access to this article

View all access options for this article.

References

1 Center for Medicaid and Medicare Services (CMS). Table 11. Prescription drug expenditures; aggregate and per capita amounts, percent distribution and average annual percent change by source of funds: selected calendar years 1990–2013. www.cms.hhs.gov/statistics/nhe/projections2003/t11.asp (accessed 2004 Jun 16).

Mahan

Sticker shock: rising prescription prices for seniors. Washington, DC: Families USA, June 2004. www.familiesusa.org/site/DocServer/Sticker_Shock.pdf?docID=3541 (accessed 2004 Jun 16).

Malkin

Goldman

Joyce

GF.

The changing face of pharmacy benefit design. Health Aff (Millwood) 2004;23: 194–9.

Olson

BM.

Approaches to pharmacy benefit management and the impact of consumer cost sharing. Clin Ther 2003;25: 250–72.

5 Center for Medicare and Medicaid Services. The facts about upcoming new benefits in Medicare. Medicare Modernization Act of 2003. February 17, 2004. Publication no. CMS-11054. www.cms.hhs.gov/medicarereform (accessed 2005 Jan 3).

Robinson

JC.

Reinvention of health insurance in the consumer era. JAMA 2004;291: 1880–6.

7 Kaiser Family Foundation. Prescription drug trends. Trends and indicators in the changing health care marketplace, 2004 update. Publication no. 7031. www.kff.org/insurance/7031/index.cfm (accessed 2004 Jul 8).

Joyce

Escarce

Solomon

Goldman

DP.

Employer drug benefit plans and spending on prescription drugs. JAMA 2002;288: 1733–9.

Hensley

Employers use co-payments to keep drug costs in line. Wall Street Journal May 10, 2004. http://webreprints.djreprints.com/1077151057910.html (accessed 2005 Jan 3).

10.

Hensley

From ‘one size fits all’ to tailored co-payments. Wall Street Journal June 16, 2004.

11.

Tamblyn

Laprise

Hanley

Abrahamowicz

Scott

Mayo

Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285: 421–9.

12.

Motheral

Fairman

KA.

Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care 2001;39: 1293–304.

13.

Fairman

Motheral

Henderson

RR.

Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther 2003;25: 3147–61.

14.

Huskamp

Deverka

Epstein

McGuigan

Frank

RG.

The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003;349: 2224–32.

15.

Goldman

Joyce

Escarce

Pace

Solomon

Laouri

Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004;291: 2344–50.

16.

Motheral

Henderson

The effect of copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am J Managed Care 1999;5: 1383–94.

17.

Nair

Wolfe

Valuck

McCollum

Ganther

Lewis

SJ.

Effects of a 3-tier pharmacy benefit design on prescription purchasing behavior of individuals with chronic disease. J Managed Care Pharm 2003;2: 123–33.

18.

Harris

Stergachis

Ried

DL.

The effect of co-payments on utilization and costs of pharmaceuticals in a health maintenance organization. Med Care 1990;23: 907–17.

19.

Kamal-Bahl

Briesacher

How do incentive based formularies influence drug selection and spending for hypertension?

Health Aff (Millwood) 2004;23: 227–36.

20.

Ellis

Erickson

Stevenson

Bernstein

Stiles

Fendrick

AM.

Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19: 638–45.

21.

Heisler

Langa

Eby

Fendrick

Kabeto

Piette

JD.

The health effects of restricting prescription medication use due to cost. Med Care 2004;42: 626–34.

22.

Briesacher

Kamal-Bahl

Hochberg

Orwig

Kahler

KH.

Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. Arch Intern Med 2004;164: 1679–84.

23.

Meissner

Moore

Shinogle

Reeder

Little

JM.

Effects of an increase in prescription copayment on utilization of low-sedating antihistamine and nasal steroids. J Managed Care Pharm 2004;10: 226–33.

24.

Schneeweiss

Soumerai

Maclure

Dormuth

Walker

Glynn

RJ.

Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther 2003;74: 388–400.